PRPO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -17.94% compared to Precipio's net margin of -28.21%. Precipio's return on equity of -25.53% beat Azenta's return on equity of -3.48%.

Precipio has a consensus price target of --, signalling upside risk potential of 68.81%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 36.8%. Given that Precipio has higher upside potential than Azenta, analysts believe Precipio is more attractive than Azenta.

Precipio has a beta of 1.280, which suggesting that the stock is 28.032% more volatile than S&P 500. In comparison Azenta has a beta of 1.616, suggesting its more volatile than the S&P 500 by 61.626%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $4.9M, which are smaller than Azenta quarterly revenues of $143.4M. Precipio's net income of -$884K is higher than Azenta's net income of -$40.5M. Notably, Precipio's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.83x versus 2.31x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of -17.94% compared to Precipio's net margin of -48.04%. Precipio's return on equity of -25.53% beat Bionano Genomics's return on equity of -141.6%.

Precipio has a consensus price target of --, signalling upside risk potential of 68.81%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 98.2%. Given that Bionano Genomics has higher upside potential than Precipio, analysts believe Bionano Genomics is more attractive than Precipio.

Precipio has a beta of 1.280, which suggesting that the stock is 28.032% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.277, suggesting its more volatile than the S&P 500 by 127.739%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $4.9M, which are smaller than Bionano Genomics quarterly revenues of $6.5M. Precipio's net income of -$884K is higher than Bionano Genomics's net income of -$3.1M. Notably, Precipio's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.83x versus 0.16x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -17.94% compared to Precipio's net margin of 2.17%. Precipio's return on equity of -25.53% beat Bruker's return on equity of 4.53%.

Precipio has a consensus price target of --, signalling upside risk potential of 68.81%. On the other hand Bruker has an analysts' consensus of $55.97 which suggests that it could grow by 40.39%. Given that Precipio has higher upside potential than Bruker, analysts believe Precipio is more attractive than Bruker.

Precipio has a beta of 1.280, which suggesting that the stock is 28.032% more volatile than S&P 500. In comparison Bruker has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.599%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.5% to investors and pays a quarterly dividend of $0.05 per share. Precipio pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Precipio quarterly revenues are $4.9M, which are smaller than Bruker quarterly revenues of $801.4M. Precipio's net income of -$884K is lower than Bruker's net income of $17.4M. Notably, Precipio's price-to-earnings ratio is -- while Bruker's PE ratio is 76.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.83x versus 1.75x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -17.94% compared to Precipio's net margin of -231.19%. Precipio's return on equity of -25.53% beat Harvard Bioscience's return on equity of -103.83%.

Precipio has a consensus price target of --, signalling upside risk potential of 68.81%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 473.18%. Given that Harvard Bioscience has higher upside potential than Precipio, analysts believe Harvard Bioscience is more attractive than Precipio.

Precipio has a beta of 1.280, which suggesting that the stock is 28.032% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.863%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $4.9M, which are smaller than Harvard Bioscience quarterly revenues of $21.8M. Precipio's net income of -$884K is higher than Harvard Bioscience's net income of -$50.3M. Notably, Precipio's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.83x versus 0.25x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.